Skip to content

Study · Animal study (in vivo) · pig · 2018

14 results

Mitoprotection attenuates myocardial vascular impairment in porcine metabolic syndrome.

Yuan F, Hedayat AF, Ferguson CM, Lerman A, Lerman LO, Eirin A

American journal of physiology. Heart and circulatory physiology1 Dec 2017Cited by 17 (Europe PMC)

PMID29196345 (opens in a new tab)PMCIDPMC5899259 (opens in a new tab)DOI10.1152/ajpheart.00431.2017 (opens in a new tab)PepBankPUB-29196345
Source linkPubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide normalized coronary endothelial cell mitochondrial density.

    In plain wordsIn pigs with metabolic syndrome, elamipretide restored the number of mitochondria in heart blood vessel lining cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCoronary EC mitochondrial density
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    EC mitochondrial density decreased in MetS animals compared with lean animals but normalized in MetS + ELAM animals.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide attenuated coronary endothelial cell oxidative stress.

    In plain wordsIn pigs with metabolic syndrome, elamipretide reduced oxidative stress in heart blood vessel lining cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCoronary EC oxidative stress
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also attenuated EC oxidative stress and apoptosis and improved subendocardial microvascular density.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide attenuated coronary endothelial cell apoptosis.

    In plain wordsIn pigs with metabolic syndrome, elamipretide reduced cell death in heart blood vessel lining cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCoronary EC apoptosis
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Cell viability and death · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also attenuated EC oxidative stress and apoptosis and improved subendocardial microvascular density.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide improved subendocardial microvascular density.

    In plain wordsIn pigs with metabolic syndrome, elamipretide improved the density of small blood vessels in the inner heart wall.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSubendocardial microvascular density
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also attenuated EC oxidative stress and apoptosis and improved subendocardial microvascular density.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide decreased coronary retention of endothelial progenitor cells.

    In plain wordsIn pigs with metabolic syndrome, elamipretide reduced the trapping of repair cells in heart blood vessels.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCoronary retention of EPCs
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM-induced vasculoprotection was reflected by decreased coronary retention of EPCs.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide partly improved endothelial nitric oxide synthase immunoreactivity.

    In plain wordsIn pigs with metabolic syndrome, elamipretide partly improved a nitric oxide enzyme level in heart blood vessels.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseeNOS immunoreactivity
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also partly improved endothelial nitric oxide synthase immunoreactivity, coronary endothelial function, and vessel maturity, whereas myocardial perfusion was unaffected.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide partly improved coronary endothelial function.

    In plain wordsIn pigs with metabolic syndrome, elamipretide partly improved heart blood vessel lining function.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCoronary endothelial function
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also partly improved endothelial nitric oxide synthase immunoreactivity, coronary endothelial function, and vessel maturity, whereas myocardial perfusion was unaffected.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide partly improved vessel maturity.

    In plain wordsIn pigs with metabolic syndrome, elamipretide partly improved the maturity of heart blood vessels.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCoronary vessel maturity
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also partly improved endothelial nitric oxide synthase immunoreactivity, coronary endothelial function, and vessel maturity, whereas myocardial perfusion was unaffected.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide did not change myocardial perfusion.

    In plain wordsIn pigs with metabolic syndrome, elamipretide did not change blood flow to the heart muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeMyocardial perfusion
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    ELAM also partly improved endothelial nitric oxide synthase immunoreactivity, coronary endothelial function, and vessel maturity, whereas myocardial perfusion was unaffected.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, chronic elamipretide treatment decreased release of markers of vascular injury.

    In plain wordsIn pigs with metabolic syndrome, elamipretide reduced the release of markers of blood vessel injury.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseRelease of markers of vascular injury
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    The present study shows that chronic mitoprotection preserved coronary endothelial cell mitochondria and decreased vascular injury, subendocardial microvascular loss, coronary retention of endothelial progenitor cells, and release of markers of vascular injury.
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide treatment did not prevent development of obesity; untreated and elamipretide-treated MetS pigs developed similar MetS.

    In plain wordsIn pigs with metabolic syndrome, elamipretide did not stop weight gain; treated and untreated pigs developed similar metabolic syndrome.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeObesity (similar in treated and untreated MetS)
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    MetS and MetS + ELAM pigs developed similar MetS (obesity, hyperlipidemia, insulin resistance, and hypertension).
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide treatment did not prevent hyperlipidemia; untreated and elamipretide-treated MetS pigs developed similar MetS.

    In plain wordsIn pigs with metabolic syndrome, elamipretide did not stop high blood fats; treated and untreated pigs were similar.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeHyperlipidemia (similar in treated and untreated MetS)
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    MetS and MetS + ELAM pigs developed similar MetS (obesity, hyperlipidemia, insulin resistance, and hypertension).
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide treatment did not prevent insulin resistance; untreated and elamipretide-treated MetS pigs developed similar MetS.

    In plain wordsIn pigs with metabolic syndrome, elamipretide did not stop insulin resistance; treated and untreated pigs were similar.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeInsulin resistance (similar in treated and untreated MetS)
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    MetS and MetS + ELAM pigs developed similar MetS (obesity, hyperlipidemia, insulin resistance, and hypertension).
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In pigs with diet-induced metabolic syndrome, elamipretide treatment did not prevent hypertension; untreated and elamipretide-treated MetS pigs developed similar MetS.

    In plain wordsIn pigs with metabolic syndrome, elamipretide did not stop high blood pressure; treated and untreated pigs were similar.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeHypertension (similar in treated and untreated MetS)
    Study

    pign = 6

    Diet-induced metabolic syndrome in pigs
    Comparator
    Untreated MetS pigs
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.1 mg/kg once daily · subcutaneous · 4 weeksAs given in this study (pig).

    Source sentences

    Summary
    MetS and MetS + ELAM pigs developed similar MetS (obesity, hyperlipidemia, insulin resistance, and hypertension).
    1 context sentence
    Summary · context
    Pigs were studied after 16 wk of diet-induced MetS, MetS treated for the last 4 wk with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg/kg sc once daily), and lean controls ( n = 6 each).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.